Vaccinex (VCNX) Reports Q4 Revenues Beat Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
March 13, 2019 7:17 AM EDTInitial data from ongoing open label study of pepinemab (VX15/2503) in combination with avelumab in non-small cell lung cancer expected in 2Q 2019
Enrollment in cohort B of the Phase 2 SIGNAL Huntingtons disease trial complete; data expected in 2H 2020
ROCHESTER, N.Y., March 13, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announced financial... More
